A major global effort is currently ongoing to search for therapeutics and vaccines to treat or prevent infection by the SARS-CoV-2 virus. Repurposing existing entities is one attractive approach. The heparan sulfate mimetic pixatimod is a clinical-stage synthetic sulfated compound that is a potent inhibitor of the glycosidase heparanase, and has known anti-cancer, anti-inflammatory and also antiviral properties. Here we show that pixatimod binds directly to the SARS-CoV-2 spike protein S1 receptor binding domain (RBD) and alters its conformation. Notably, this site overlaps with the known ACE2 binding site in the S1 RBD. We find that pixatimod inhibits binding of recombinant S1 RBD to Vero cells which express the ACE2 receptor. Moreover, in assays with three different isolates of live SARS-CoV-2 virus we show that pixatimod effectively inhibits viral infection of Vero cells. Importantly, its potency is well within its safe therapeutic dose range. These data provide evidence that pixatimod is a potent antiviral agent against SARS-CoV-2. Together with its other known activities this provides a strong rationale for its clinical investigation as a new multimodal therapeutic for the current COVID-19 pandemic.

No abstract

No abstract

The IEEE standard PSL is now a commonly accepted specification language for the Assertion-Based Verification (ABV) of complex systems. In addition to its Boolean and Temporal layers, it is syntactically extended with the Modeling layer that borrows the syntax of the HDL is which the PSL assertions are included, to manage auxiliary variables. In this paper we propose a formal, operational, semantics of PSL enriched with the Modeling layer. Moreover we describe the implementation of this notion in our tool for the dynamic ABV of SystemC TLM models. Illustrative examples are presented.

No abstract